Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Acellular Fetal Bovine Dermal Matrix for Treatment of Chronic Ulcerations of the Midfoot Associated With Charcot Neuroarthropathy
Kavros, Steven J.

Mayo Clinic

Foot & Ankle Specialist | June 20, 2012 | Volume: 5 | Issue: 4 | Pages: 230-234

10.1177/1938640012449037 | PMID 22715495 Get It

Background. Gross deformity of the foot in Charcot neuroarthropathy can lead to collapse and subsequent ulceration, infection, amputation, or premature death. This study evaluated healing of midfoot ulcerations of Charcot neuroarthropathy using PriMatrix, a novel acellular fetal bovine dermal matrix. Methods. In this retrospective analysis, 20 patients with ulcerations of the midfoot associated with Charcot neuroarthropathy were treated with either PriMatrix in addition to standard wound care (PriMatrix group,n = 12) or standard wound care alone (control group, n = 8). All patients had chronic, nonhealing foot ulcerations of at least 2250 mm 3 for a minimum of 30 days duration. All foot ulcerations were full thickness with subcutaneous involvement. Ankle brachial index ≥0.90 and/or transcutaneous oximetry (TcPo 2 ) ≥40 mm Hg at the periulcer site was necessary for inclusion. Patients were excluded if they had acute or chronic osteomyelitis of the foot. Results. Demography, risk factors, baseline severity of Charcot neuroarthropathy, and wound volume (control 4078 mm 3 , PriMatrix 3737.5 mm 3 , P = nonsignificant) were similar between treatment groups. Mean time to healing in the PriMatrix group (116 days, 95% CI = 109-123) was significantly shorter than in the control group (180 days, 95% confidence interval [CI] = 171-188); P < .0001. A significantly faster rate of healing was observed with PriMatrix (87.9 mm 3 /wk, 95% CI = 115.2% to 60.6%) compared with control (59.0 mm 3 /wk, 95% CI = 72.8% to 45.3%); P < .0001). Conclusions. The significantly faster rate of healing and steeper slope of volume reduction in the PriMatrix group warrants further investigation into its effects on healing of neuropathic ulcerations and potential limb salvage. Levels of Evidence: Therapeutic, Level IV
Increased Mortality of Patients With Diabetes Reporting Severe Hypoglycemia
Houten, Holly K. Van , Shah, Nilay D. , Wermers, Robert A. , Smith, Steven A., McCoy, Rozalina G. , Ziegenfuss, Jeanette Y.

Mayo Clinic

Diabetes Care | June 15, 2012 | Volume: 35 | Issue: 9 | Pages: 1897-1901

10.2337/dc11-2054 | PMID 22699297 Get It

OBJECTIVE Hypoglycemia is a cause of significant morbidity among patients with diabetes and may be associated with greater risk of death. We conducted a retrospective study to determine whether patient self-report of severe hypoglycemia is associated with increased mortality. RESEARCH DESIGN AND METHODS Adult patients (N = 1,020) seen in a specialty diabetes clinic between August 2005 and July 2006 were questioned about frequency of hypoglycemia during a preencounter interview; 7 were lost to follow-up and excluded from analysis. Mild hypoglycemia was defined as symptoms managed without assistance, and severe hypoglycemia was defined as symptoms requiring external assistance. Mortality data, demographics, clinical characteristics, and Charlson comorbidity index (CCI) were obtained from the electronic medical record after 5 years. Patients were stratified by self-report of hypoglycemia at baseline, demographics were compared using the two-sample t test, and risk of death was expressed as odds ratio (95% CI). Associations were controlled for age, sex, diabetes type and duration, CCI, HbA1c, and report of severe hypoglycemia. RESULTS In total, 1,013 patients with type 1 (21.3%) and type 2 (78.7%) diabetes were questioned about hypoglycemia. Among these, 625 (61.7%) reported any hypoglycemia, and 76 (7.5%) reported severe hypoglycemia. After 5 years, patients who reported severe hypoglycemia had 3.4-fold higher mortality (95% CI 1.5–7.4; P = 0.005) compared with those who reported mild/no hypoglycemia. CONCLUSIONS Self-report of severe hypoglycemia is associated with 3.4-fold increased risk of death. Patient-reported outcomes, including patient-reported hypoglycemia, may therefore augment risk stratification and disease management of patients with diabetes.
Prognostic Value of Treadmill Exercise Testing
Roger, Véronique L. , Jacobsen, Steven J. , Pellikka, Patricia A. , Miller, Todd D., Bailey, Kent R. , Gersh, Bernard J., Pellikka, Patricia A

Mayo Clinic

Circulation | June 12, 2012 | Volume: 98 | Issue: 25 | Pages: 2836-2841

10.1161/01.cir.98.25.2836 | PMID 9860784 Get It

Background —The prognostic value of treadmill exercise testing (TMET) has been studied in selected populations. The generalizability of these data to different populations and to women is uncertain. Methods and Results —A retrospective, population-based cohort study of all persons (1452 men and 741 women) who underwent TMET in years 1987 to 1989 in Olmsted County, Minnesota, was undertaken. Individuals were followed up for all-cause mortality and cardiac events (cardiac deaths, nonfatal myocardial infarction, or congestive heart failure). Sex-specific analyses were performed to determine whether the predictors of outcome and the magnitude of the associations were similar in both sexes. In men, 77 deaths and 106 cardiac events occurred during 8956 person-years of observation; in women, 46 deaths and 54 cardiac events occurred during 4801 person-years of follow-up. Exercise-induced angina, ECG changes, and workload achieved on the TMET were strongly associated with all-cause mortality and cardiac events in both sexes, and the strength of the association was similar. After adjustment, workload was the only TMET variable associated with outcome. A higher workload was associated with a reduction in the risk of cardiac events and of all-cause mortality; the protective effect of exercise capacity was strong and was similar in both sexes. Conclusions —In this population-based cohort, exercise capacity was the TMET variable that exhibited the strongest association with all-cause mortality and cardiac events. This protective effect of exercise capacity was observed in both sexes.
Congestive Heart Failure in the Community
Senni, Michele , Tribouilloy, Christophe M, Rodeheffer, Richard J. , Jacobsen, Steven J. , Evans, Jonathan M., Bailey, Kent R. , Redfield, Margaret M. , Senni, Michele

Mayo Clinic

Circulation | June 11, 2012 | Volume: 98 | Issue: 21 | Pages: 2282-2289

10.1161/01.cir.98.21.2282 | PMID 9826315 Get It

Background —Data are limited regarding the classification and prognosis of patients with congestive heart failure (CHF) in the community. Methods and Results —Using the resources of the Rochester Epidemiology Project, we evaluated all patients receiving a first diagnosis of CHF in Olmsted County, Minnesota, in 1991 (n=216). Among these patients, 88% were ≥65 years and 49% were ≥80 years of age. The prognosis of patients with a new diagnosis of CHF was poor; survival was 86±2% at 3 months, 76±3% at 1 year, and 35±3% at 5 years. Of the 216 patients, 137 (63%) had an assessment of ejection fraction. In these patients, systolic function was preserved (ejection fraction ≥50%) in 59 (43%) and reduced (ejection fraction <50%) in 78 (57%). Survival adjusted for age, sex, NYHA class, and coronary artery disease was not significantly different between patients with preserved and those with reduced systolic function (relative risk, 0.80; P =0.369). ACE inhibitors were used in only 44% of the total population with CHF. Conclusions —The present study reports the clinical characteristics and natural history of CHF as it presents in the community in the vasodilator era. CHF is a disease of the “very elderly,” frequently occurs in the setting of normal ejection fraction, and has a poor prognosis, regardless of the level of systolic function. Diagnostic and therapeutic methods are underused in the community.
Pancreas‐Sparing Total Duodenectomy for Ampullary Duodenal Neoplasms
Stauffer, John , Adkisson, Cameron D., Riegert‐Johnson, Douglas L. , Goldberg, Ross F. , Bowers, Steven P. , Asbun, Horacio J. , A Stauffer, John

Mayo Clinic

World Journal of Surgery | June 11, 2012 | Volume: 36 | Issue: 10 | Pages: 2461-2472

10.1007/s00268-012-1672-3 | PMID 22689018 Get It

AbstractBackgroundAmpullary and extensive periampullary lesions can be difficult to treat and often require pancreaticoduodenectomy (PD) for complete removal, even if benign. However, PD may be overtreatment for noninvasive lesions, and pancreas‐sparing total duodenectomy (PSTD) is an emerging valid surgical option for selected cases.MethodsWe reviewed patients undergoing PSTD at our institution over 16 months and a comparison group who had undergone PD for benign duodenal disease over the past 15 years. We also reviewed cases in the English‐language literature and performed a meta‐analysis of those patients who had undergone PSTD.ResultsPSTD had been performed in four patients, who had an average hospital length of stay (LOS) of 13 days; two of them experienced complications. None required conversion to PD, experienced a postoperative fistula or endocrine or exocrine insufficiency, or required intensive care. Two of the PSTDs were performed laparoscopically. Open PD for benign duodenal disease was performed in 22 patients, with overall morbidity and pancreas fistula rates of 82 and 27 %, respectively. The meta‐analysis found 128 unique cases of PSTD with morbidity and mortality rates of 46.4 and 2.3 %, respectively. Pancreaticobiliary leak was seen in 20 %, with an average LOS of 17 days.ConclusionsAlthough PSTD can be used to avoid PD and can be performed laparoscopically, it is technically challenging and still associated with morbidity.
Genotype – phenotype correlation in FAP
Zeldenrust, Steven R.

Mayo Clinic

Amyloid | May 24, 2012 | Volume: 19 | Issue: sup1 | Pages: 22-24

10.3109/13506129.2012.665400 | PMID 22620962 Get It

Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience
D’Souza, Anita , Lacy, Martha Q. , Kumar, Shaji , Hayman, Suzanne R. , Dingli, David , Zeldenrust, Steven R., Kyle, Robert A. , Ansell, Stephen M. , Inwards, David J. , Johnston, Patrick B. , Micallef, Ivana N. , Porrata, Luis F. , Litzow, Mark R. , Gastineau, Dennis A., Dispenzieri, Angela , Gertz, Morie A. , Buadi, Francis K. , Hogan, William J. , D'Souza, Anita , Dispenzieri, Angela , Dingli, David

Mayo Clinic

Blood | May 20, 2012 | Volume: 120 | Issue: 1 | Pages: 56-62

10.1182/blood-2012-04-423178 | PMID 22611150 Get It

AbstractThe POEMS syndrome (polyradiculoneuropathy, organomegaly, multiple endocrinopathies, monoclonal protein, skin changes) is a rare disease associated with a plasma cell dyscrasia. Patients with disseminated POEMS can be treated with high-dose therapy and autologous stem cell transplantation (ASCT). While clinical improvement is nearly universal in these patients, the long-term outcomes after transplantation are unclear. We therefore assessed the long-term clinical outcomes of 59 POEMS patients treated with ASCT at our institution. With a median follow-up of 45 months, 14 patients have progressed with a progression-free survival of 98% and 75% at 1 and 5 years, respectively. Factors associated with progression have included an IgG-λ monoclonal component (hazard ratio [HR] 7.5; 95% confidence interval [CI], 2.3-28.3; P = .0008), fluorodeoxyglucose-avid lesions on baseline positron emission tomography (HR 6.4; 95% CI, 1.2-120; P = .03), lack of complete hematologic response (HR 5.4; 95% CI, 1.8-16.7; P = .003), and patients aged 50 years or younger at transplantation (HR 4.4; 95% CI, 1.3-20; P = .01). The most common progression events have been radiologic followed by rising VEGF. Symptomatic progression has been rare. Most patients could be salvaged with immunomodulatory drugs or radiation. The 5-year survival is 94%. Herein, we describe a system of monitoring response and progression among patients with POEMS after ASCT.
Highly fatal fast-channel syndrome caused by AChR ɛ subunit mutation at the agonist binding site
Shen, Xin‐Ming , Brengman, Joan M., Edvardson, Simon , Sine, Steve M., Engel, Andrew G. , Sine, Steven M.

Mayo Clinic

Neurology | May 17, 2012 | Volume: 79 | Issue: 5 | Pages: 449-454

10.1212/wnl.0b013e31825b5bda | PMID 22592360 Get It

The Role of Preoperative Bilateral Breast Magnetic Resonance Imaging in Patient Selection for Partial Breast Irradiation in Ductal CarcinomaIn Situ
Kowalchik, Kristin, Vallow, Laura A., McDonough, Michelle, Thomas, Colleen S. , Peterson, Jennifer , Adkisson, Cameron D., Serago, Christopher F., Buskirk, Steven J., McLaughlin, Sarah A., Heckman, Michael G.

Mayo Clinic

International Journal of Surgical Oncology | May 13, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-6

10.1155/2012/206342 | PMID 22655183 Get It

Purpose. Women with ductal carcinomain situ(DCIS) are often candidates for breast-conserving therapy, and one option for radiation treatment is partial breast irradiation (PBI). This study evaluates the use of preoperative breast magnetic resonance imaging (MRI) for PBI selection in DCIS patients.Methods. Between 2002 and 2009, 136 women with newly diagnosed DCIS underwent a preoperative bilateral breast MRI at Mayo Clinic in Florida. One hundred seventeen women were deemed eligible for PBI by the NSABP B-39 (National Surgical Adjuvant Breast and Bowel Project, Protocol B-39) inclusion criteria using physical examination, mammogram, and/or ultrasound. MRIs were reviewed for their impact on patient eligibility, and findings were pathologically confirmed.Results. Of the 117 patients, 23 (20%) were found ineligible because of pathologically proven MRI findings. MRI detected additional ipsilateral breast cancer in 21 (18%) patients. Of these women, 15 (13%) had more extensive disease than originally noted before MRI, and 6 (5%) had multicentric disease in the ipsilateral breast. In addition, contralateral breast cancer was detected in 4 (4%).Conclusions. Preoperative breast MRI altered the PBI recommendations for 20% of women. Bilateral breast MRI should be an integral part of the preoperative evaluation of all patients with DCIS being considered for PBI.
Prognostic value of the MIB-1 labeling index for central neurocytomas
Rades, Dirk , Fehlauer, Fabian, Schild, Steven E.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 62 | Issue: 6 | Pages: 987-989

10.1212/01.wnl.0000115392.21898.e3 | PMID 15037708 Get It